A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.

摘要

There have been many phase III randomized controlled trials (RCTs) assessing the role of trastuzumab in addition to adjuvant chemotherapy for patients with HER-2-positive advanced breast cancer (1-4). However, the results were not consistent. Therefore, to quantitatively summarize the currently available clinical findings, we conducted a meta-analysis to investigate whether the addition of trastuzumab to chemotherapy is superior to chemotherapy alone for HER-2-positive advanced or metastatic breast cancer.